Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
CHOSA Oncology AB (publ) ("CHOSA" or the "Company") has as expected received the tax credit from the Danish "Tax Credit Order" of 5.1 mDKK equivalent to 7.8 mSEK. The tax credit is equal to the tax value of the expenses attributable to research and development in the 2022 financial year of Rhovac ApS. The received tax credit is in line with previously communicated assumptions.
CEO Peter Buhl comments: "We are happy to announce that the Danish tax authorities have now refunded the expenses as applied for, used for clinical development. The funds will support CHOSA's Business development and partnering activities, to ensure that LiPlaCis® and its platinum DRP® biomarker reach cancer patients, providing them with the benefits they need."
At this year ASCO, CHOSA published successful phase 2b data from a study in metastatic breast cancer. This data is a continuation of the already published data for the platinum DRP's success in finding platinum responders in lung cancer patients. Cisplatin is a mainstay in many cancer therapies and partakes in many of the most successful new immuno-oncology treatments. Our DRP can be an important partner in providing tomorrow's personal therapy. We are confident in the potential of our products and believe they will significantly impact the fight against cancer.
This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 01-12-2023 14:11 CET.